Heart surgery is done to correct problems with the heart. More than half a million heart surgeries are done each year in the United States for a variety of heart problems. Heart surgery is used to correct heart problems in children and adults. This article discusses heart surgeries for adults. For more information about heart surgeries for children, see the Diseases and Conditions Index articles on congenital heart defects, holes in the heart, and tetralogy of Fallot.
The most common type of heart surgery for adults is coronary artery bypass grafting (CABG). During CABG, surgeons use healthy arteries or veins taken from another part of the body to bypass (that is, go around) blocked arteries. CABG relieves chest pain and reduces the risk of heart attack.
Infants born with a severely underdeveloped heart are more likely to survive to their first birthday when treated with a new shunt procedure - yet it may not be the safest surgery long term, according to research presented at the American Heart Association's Scientific Sessions 2009.
By matching children with rare or life-threatening diseases and modelling potential disease progression, researchers hope to find new routes forward.
Millar Instruments, Inc., developer and manufacturer of Mikro-Tip® pressure transducer catheters and pressure-volume (P-V) systems, and Transonic Systems, Inc., global leader in the design, manufacture and marketing of flow measurement devices, today announce a new distribution partnership.
An innovative method is being used to repair the breastbone after it is intentionally broken to provide access to the heart during open-heart surgery. The technique uses a state-of-the-art adhesive that rapidly bonds to bone and accelerates the recovery process.
Texas Children's Hospital is the nation's first pediatric hospital to discharge a child while on an intracorporeal ventricular assist device (VAD), a feat previously accomplished only at adult institutions. The patient, 16-year-old Francisco "Frank" De Santiago, who was implanted with a mechanical heart pump called the HeartMate II on May 19, 2009, was discharged on Oct. 29, 2009.
Cardiologists at the University of Illinois Medical Center are using a new heart pump that can be inserted without the need for surgery and allows them to treat high-risk patients with a procedure to unblock their heart arteries.
Imagine waking up after surgery to find out you have lost your sight—permanently. Although rare, postoperative visual loss is a well-recognized complication of anesthesia and surgery that is more common after certain types of procedures and in some groups of patients, according to a study in the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
NeoChord, Inc., a venture-backed, Minneapolis-based medical technology company, announced today that it has enrolled the first patient in its European clinical trial. The trial, known as TACT (transapical artificial chordae tendineae) is being conducted in Germany, Denmark, Czech Republic and Norway.
Clinical trial results published in this week’s Journal of the American College of Cardiology (JACC) describe six-month outcomes for patients using the Melody® Transcatheter Pulmonary Valve from Medtronic, Inc.. The valve is implanted through a catheter procedure instead of open-heart surgery in patients with congenital heart disease affecting the function of their pulmonary valve.
PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.
Results from a clinical study presented at the 2009 American Society of Anesthesiologists (ASA) Meeting suggest that elevated preoperative levels of the B-type natriuretic peptide (BNP) biomarker may predict hospital length of stay and mortality after primary coronary artery bypass graft surgery better than measurements of elevated postoperative BNP levels.
Two studies presented at this week's Annual Meeting of the American Society of Anesthesiologists offer new information as to how physicians might better determine which surgical patients may be at risk for developing kidney injury after surgery.
Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.
OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented today at the American Association of Anesthesiologists (ASA) annual meeting, in New Orleans. The results from a multi-center study indicate that NBM-200MP, a continuous, non-invasive monitoring system, measures levels of oxygen saturation and hemoglobin accurately and reliably in comparison to accepted methods.
MAQUET Cardiovascular LLC, a leading, global provider of cardiovascular technologies, today celebrated and formally opened its new United States headquarters in Wayne, New Jersey. The dedication ceremony was attended by local and state dignitaries, the MAQUET leadership team, and local employees from the company's cardiovascular, critical care and surgical workplace divisions.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced the receipt of CE Mark for the ATS CryoMaze® 10-S Surgical Cryoablation Probe for the treatment of cardiac arrhythmias.
Seventy-seven year-old Hollywood legend Elizabeth Taylor announced on Tuesday she was having a Mitraclip heart procedure. Leading cardiothoracic surgeon and heart surgery expert Dr. Lishan Aklog, M.D. appeared on EmpowHer, the home of women's health online, to explain why her surgery is "experimental and controversial."
Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Scientists from the Universities of Michigan and Minnesota show in a research report published online in the FASEB Journal (http://www.fasebj.org) that gene therapy may be used to improve an ailing heart's ability to contract properly. In addition to showing gene therapy's potential for reversing the course of heart failure, it also offers a tantalizing glimpse of a day when "closed heart surgery" via gene therapy is as commonly prescribed as today's cocktail of drugs.
Methodist Hospital of Arcadia, California, has launched an integrated deployment of innovative health care information technology (HIT) solutions designed to help improve the quality of patient care and deliver operational efficiencies. MedPlus®, the health care information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), provided the integrated solution to help Methodist reduce the length of stay associated with patients and help realize gains in efficiency and revenue.